Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Cash & Equivalents (2017 - 2025)

Aclaris Therapeutics has reported Cash & Equivalents over the past 9 years, most recently at $20.0 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $20.0 million for Q4 2025, down 18.76% from a year ago — trailing twelve months through Dec 2025 was $20.0 million (down 18.76% YoY), and the annual figure for FY2025 was $20.0 million, down 18.76%.
  • Cash & Equivalents for Q4 2025 was $20.0 million at Aclaris Therapeutics, down from $25.3 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for ACRS hit a ceiling of $113.4 million in Q2 2021 and a floor of $20.0 million in Q4 2025.
  • Median Cash & Equivalents over the past 5 years was $36.1 million (2022), compared with a mean of $41.4 million.
  • Biggest five-year swings in Cash & Equivalents: surged 248.14% in 2021 and later plummeted 54.37% in 2023.
  • Aclaris Therapeutics' Cash & Equivalents stood at $27.3 million in 2021, then skyrocketed by 65.55% to $45.3 million in 2022, then dropped by 11.92% to $39.9 million in 2023, then plummeted by 38.39% to $24.6 million in 2024, then fell by 18.76% to $20.0 million in 2025.
  • The last three reported values for Cash & Equivalents were $20.0 million (Q4 2025), $25.3 million (Q3 2025), and $25.4 million (Q2 2025) per Business Quant data.